When an intercurrent event in itself is considered to be informative about the treatments' effect on patients' outcomes, the intercurrent event is often incorporated into the definition of the variable. The ICH E9 (R1) addendum refers to this as the composite strategy. In this event, speakers will present different composite estimand strategies for clinical trials, the analyses that target these estimands (e.g., trimmed means, rank-based approaches), and regulatory considerations for clinical trials with composite estimands and endpoints. A discussant will reflect on the presentations.
Who is this event intended for? Statisticians working on planning or analyzing clinical trials, or researching clinical trial methodology.
What is the benefit of attending? Attendees will have the opportunity to hear presentation of methodology and case studies that relate to composite estimands and endpoints.
13:00 BST | 14:00 CEST